Skip to main content Back to Top
Advertisement

8/3/2019

Leucovorin Calcium Injection

Products Affected - Description

    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 10 mL vial, 1 count, NDC 63323-0631-10
    • Leucovorin Calcium injection, Fresenius Kabi, 10 mg/mL, 50 mL vial, 1 count, NDC 63323-0631-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 200 mg, vial, 1 count, NDC 63323-0710-50
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 200 mg, vial, 1 count, NDC 00143-9553-01
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 50 mg, vial, 1 count, NDC 00143-9555-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Hikma, 350 mg, vial, 1 count, NDC 00143-9552-01
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 100 mg, vial, 10 count, NDC 25021-0814-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 200 mg, vial, 1 count, NDC 25021-0815-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 350 mg, vial, 1 count, NDC 25021-0816-30
    • Leucovorin Calcium lyophilized powder for injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0828-50
    • Leucovorin Calcium lyophilized powder for solution for injection, Sagent, 50 mg, vial, 10 count, NDC 25021-0813-10

Reason for the Shortage

    • Fresenius Kabi had leucovorin on shortage due to manufacturing delays and increased demand.
    • Hikma did not provide a reason for the current shortage.
    • Mylan refuses to provide availability information.
    • Sagent has leucovorin on shortage due to manufacturing delays.
    • Teva has leucovorin available.

Available Products

    • Leucovorin Calcium lyophilized powder for solution for injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0711-00
    • Leucovorin Calcium lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9554-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 100 mg, vial, 1 count, NDC 00703-5140-01
    • Leucovorin Calcium lyophilized powder for solution for injection, Teva, 350 mg, vial, 1 count, NDC 00703-5145-01

Estimated Resupply Dates

    • Fresenius Kabi has leucovorin 200 mg vials on back order and the company estimates a release date of early-August 2019. There are short-dated 10 mg/mL 50 mL vials available with an expiration date of <9 months. Leucovorin 10 mg/mL 10 mL vials are on back order and the company estimates a release date of 4th quarter 2019.
    • Hikma has leucovorin 50 mg vials are on back order and the company cannot estimate a release date. The 200 mg vials are on back order and the company estimates a release date of late-August 2019. The 350 mg vials are on allocation.
    • Sagent has leucovorin 50 mg, 100 mg, 200 mg, 350 mg, and 500 mg vials on allocation.

Updated

Updated August 3, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 6, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins